BlossomHill Therapeutics Inc (BLSM) FinancialsBLSMBlossomHill Therapeutics Inc

In the context of the broader market, BLSM competes directly with industry leaders such as RGNX and MPLT. With a market capitalization of $443.08M, it holds a significant position in the sector. When comparing efficiency, BLSM's gross margin of N/A stands against RGNX's 99.04% and MPLT's N/A. Such benchmarking helps identify whether BlossomHill Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has reported significant losses, with a net income of -23,758,000 USD for Q2 2026 and a current ratio of 5.42, indicating a strong liquidity position despite negative earnings.